Glycogen synthase kinase 3 (GSK-3) and its inhibitors : drug discovery and development /
| Corporate Author: | |
|---|---|
| Other Authors: | , , |
| Format: | eBook |
| Language: | English |
| Published: |
Hoboken, N.J. :
Wiley-Interscience,
[2006]
|
| Series: | Wiley series in drug discovery and development.
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- Glycogen synthase kinase 3: an introductory synopsis
- Glycogen synthase kinase-3[beta] (GSK-3[beta]) a key signaling enzyme: a developmental neurobiological perspective
- Role of GSK-3/Shaggy in neuronal cell biology
- The crystal structures of glycogen synthase kinase 3
- Kinase-kinase and site-site interactions in the phosphorylation of tau by GSK-3
- GSK-3, a key player in Alzheimer's disease
- Glycogen synthase kinase 3 : a target for novel mood disorder treatments
- GSK-3 and stem cells
- Glycogen synthase kinase 3 : role in neurodegeneration and neuroprotection
- Protein kinase assays for drug discovery
- Animal models with modified expression of GSK-3 for the study of its physiology and of its implications in human pathologies
- Lithium, the seminal GSK-3 inhibitor
- Inhibition of GSK-3 as therapeutic strategy in disease : efficacy of AR-A014418
- TDZD's: selective and ATP noncompetitive glycogen synthase kinase 3 inhibitors
- 3-amino pyrazoles as potent and selective glycogen kinase synthase (GSK-3) inhibitors
- Marine compounds as a new source for glycogen synthase kinase 3 inhibitors.